1. Jakobsen, JC, Katakam, KK, Schou, A et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. 2017;17:58.
2. Bielefeldt, AO, Danborg, PB, Gotzsche, PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. J R Soc Med 2016;109:381–392.
3. Schneider, LS, Nelson, JC, Clary, CM et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003;160:1277–1285.
4. Kasper, S, De Swart, H, Friis Andersen, H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005;13:884–891.
6. Kranzler, HR, Mueller, T, Cornelius, J et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006;26:13–20.
8. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:1807–1814.
18. Sweeting, MJ, Sutton, AJ, Lambert, PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–1375.
19. Friedrich, JO, Adhikari, NK, Beyene, J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007;7:5.
20. Pettinati, HM, Oslin, DW, Kampman, KM et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010;167:668–675.
21. Ravindran, AV, Teehan, MD, Bakish, D et al. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum Psychopharmacol. 1995;10:273–281.
22. De Vries, YA, Roest, AM, Beijers, L, Turner, EH, De Jonge, P. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: a meta-analysis. Eur Neuropsychopharmacol. 2016;26:1752–1759.
23. Ioannidis, JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009;169:1737–1739.
27. Ball, WA, Snavely, DB, Hargreaves, RJ, Szegedi, A, Lines, C, Reines, SA. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Hum Psychopharmacol. 2014;29:568–577.
28. Nyth, AL, Gottfries, CG, Lyby, K et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138–145.
30. Mathews, M, Gommoll, C, Chen, D, Nunez, R, Khan, A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2015;30:67–74.
35. Feighner, JP, Overo, K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999;60:824–830.
36. Groenwold, RH, Rovers, MM, Lubsen, J, Van Der Heijden, g. Subgroup effects despite homogeneous heterogeneity test results. BMC Med Res Methodol 2010;10:43.
37. Loo, H, Hale, A, D’haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239–247.
41. Ostergaard, SD. Do not blame the SSRIs: blame the Hamilton Depression Rating Scale. Acta Neuropsychiatr. 2017:1–3.
42. Wernicke, JF, Dunlop, SR, Dornseif, BE, Zerbe, RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164–168.
43. Wernicke, JF, Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988;24:183–188.
44. Mendels, J, Kiev, A, Fabre, LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety. 1999;9:54–60.
51. US Food and Drug Administration, Center for Drug Evaluation and Research. Paxil NDA 020031 approval letter, statistical review, 1992.
53. Fabre, LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992;53(Suppl):40–43.
55. Hieronymus, F, Nilsson, S, Eriksson, E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry. 2016;6:e834.
56. Hieronymus, F, Emilsson, JF, Nilsson, S, Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry. 2016;21:523–530.
57. Bech, P. Is the antidepressant effect of second-generation antidepressants a myth? Psyhcological Medicine 2010;40:181–186.